Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

FDA Approval of Olaparib for BRCA-Mutated Ovarian Cancer Treatment – 2014

FDA Approval of Olaparib for BRCA-Mutated Ovarian Cancer Treatment – 2014

Approved by the FDA on 19 December 2014, Lynparza began being used to treat women with advanced ovarian cancer carrying a BRCA gene mutation (genetic alteration).

Lynparza blocks the PARP enzyme, which repairs DNA damage. Besides the general side effects of most cancer drugs, caution is needed regarding development of Myelodysplastic Syndrome/Acute Myeloid Leukemia.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

FDA Approval of Olaparib for BRCA-Mutated Ovarian Cancer Treatment – 2014

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy